Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
RhoA protects the mouse heart against ischemia/reperfusion injury
Sunny Yang Xiang, … , Gerald W. Dorn II, Joan Heller Brown
Sunny Yang Xiang, … , Gerald W. Dorn II, Joan Heller Brown
Published July 11, 2011
Citation Information: J Clin Invest. 2011;121(8):3269-3276. https://doi.org/10.1172/JCI44371.
View: Text | PDF
Research Article Cardiology

RhoA protects the mouse heart against ischemia/reperfusion injury

  • Text
  • PDF
Abstract

The small GTPase RhoA serves as a nodal point for signaling through hormones and mechanical stretch. However, the role of RhoA signaling in cardiac pathophysiology is poorly understood. To address this issue, we generated mice with cardiomyocyte-specific conditional expression of low levels of activated RhoA (CA-RhoA mice) and demonstrated that they exhibited no overt cardiomyopathy. When challenged by in vivo or ex vivo ischemia/reperfusion (I/R), however, the CA-RhoA mice exhibited strikingly increased tolerance to injury, which was manifest as reduced myocardial lactate dehydrogenase (LDH) release and infarct size and improved contractile function. PKD was robustly activated in CA-RhoA hearts. The cardioprotection afforded by RhoA was reversed by PKD inhibition. The hypothesis that activated RhoA and PKD serve protective physiological functions during I/R was supported by several lines of evidence. In WT mice, both RhoA and PKD were rapidly activated during I/R, and blocking PKD augmented I/R injury. In addition, cardiac-specific RhoA-knockout mice showed reduced PKD activation after I/R and strikingly decreased tolerance to I/R injury, as shown by increased infarct size and LDH release. Collectively, our findings provide strong support for the concept that RhoA signaling in adult cardiomyocytes promotes survival. They also reveal unexpected roles for PKD as a downstream mediator of RhoA and in cardioprotection against I/R.

Authors

Sunny Yang Xiang, Davy Vanhoutte, Dominic P. Del Re, Nicole H. Purcell, Haiyun Ling, Indroneal Banerjee, Julie Bossuyt, Richard A. Lang, Yi Zheng, Scot J. Matkovich, Shigeki Miyamoto, Jeffery D. Molkentin, Gerald W. Dorn II, Joan Heller Brown

×

Figure 1

Characterization of conditional cardiac-specific RhoA transgenic mice.

Options: View larger image (or click on image) Download as PowerPoint
Characterization of conditional cardiac-specific RhoA transgenic mice.
(...
(A) Top panel: time line of Dox administration and sacrifice of animals for analysis. Bottom panel: activation and expression of endogenous (WT) and transgenic (HA-tagged) RhoA in the LV of CA-RhoA mouse hearts from lines 7 and 25 at various times after Dox removal (off Dox). (B) Representative image of hearts from tTA and CA-RhoA (line 25) mice (top panel). Scale bar: 5 mm. Heart weight (HW) to body weight (BW) ratio and heart weight to tibial length (TL) ratio from WT, tTA, and CA-RhoA mice at 8 weeks or 8 months after Dox removal. Data are shown as mean ± SEM. (C) Representative staining of histological sections in tTA and CA-RhoA (line 25) hearts by H&E staining (top). Scale bars: 2 mm. Tri staining (middle) and TRITC-conjugated, WGA staining of cell membranes (bottom). Scale bars: 50 μm.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts